|Post IPO Valuation|
|Phone||+32 (0)9 262 00 00|
|POST IPO FUNDING|
|Post IPO Equity, 2/2013 ||€31.5M|
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.